CELONIB 400MG TABLET

About

Celonib 400mg Tablet is a targeted therapy belonging to the class of tyrosine kinase inhibitors (TKIs). It works by selectively inhibiting specific tyrosine kinases that are crucial for the proliferation and survival of cancer cells. By blocking these aberrant signaling pathways, Celonib prevents the uncontrolled growth and division of malignant cells, leading to tumor regression or stabilization. This targeted approach offers a more specific treatment option compared to traditional chemotherapy, often with a different spectrum of side effects.

Administered orally, Celonib is a cornerstone in the treatment of certain hematologic malignancies and solid tumors driven by specific genetic mutations. Its efficacy is often linked to the presence of particular oncogenic fusion proteins or mutations, such as the Philadelphia chromosome (BCR-ABL) in chronic myeloid leukemia. Regular monitoring of blood counts, liver function, and cardiac parameters is essential during treatment. The dosage is individualized based on the patient's response and tolerability, aiming for long-term disease control.

Uses

• Treatment of chronic myeloid leukemia (CML)
• Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Therapy for gastrointestinal stromal tumors (GIST)
• Used in certain myelodysplastic/myeloproliferative diseases

Directions For Use

Take Celonib 400mg Tablet orally, usually once daily, with a meal and a large glass of water to minimize gastrointestinal irritation. Do not crush or chew the tablet.

Benefits

• Targets specific cancer-driving pathways
• Highly effective in specific genetically defined cancers
• Often leads to durable remissions and long-term disease control
• Administered orally, offering convenience to patients
• Generally better tolerated than conventional chemotherapy
• Improves progression-free and overall survival rates

Side Effects

• Fluid retention (periorbital edema, peripheral edema)
• Nausea and vomiting
• Diarrhea
• Muscle cramps and musculoskeletal pain
• Fatigue
• Rash
• Headache
• Myelosuppression (neutropenia, thrombocytopenia)
• Liver enzyme elevations
• Abdominal pain
• Cardiac dysfunction (rare, dose-dependent)
• Hypothyroidism (rare)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it may increase the risk of liver toxicity when combined with Celonib.
• Pregnancy - Celonib is not recommended during pregnancy due to potential fetal harm. Use effective contraception during treatment.
• Breastfeeding - Breastfeeding is not advised during Celonib therapy as the drug may be excreted in breast milk and harm the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and liver function should be monitored closely.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but caution is advised in severe cases.
• Lung - Monitor for pulmonary adverse events, including interstitial lung disease or pleural effusion, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.